Biological Activities of Naringin: Comparison
Please note this is a comparison between Version 2 by Peter Tang and Version 1 by Mutang Zhang.

Naringin (NG), a natural flavanone glycoside, possesses a multitude of pharmacological properties, encompassing anti-inflammatory, sedative, antioxidant, anticancer, anti-osteoporosis, and lipid-lowering functions, and serves as a facilitator for the absorption of other drugs. 

  • naringin
  • physiological activity
  • bioavailability

1. Introduction

Naringin (NG) known as 4′,5,7-Trihydroxyflavanone 7-Rhamnoglucoside is a compound that falls under the classification of dihydroflavonoids. This complex compound comprises 4′,5,7-hydroxyflavone (saccharide ligand) conjoined with rhamnose-β-1,2-glucose [1]. The primary source of naringin (NG) is citrus fruit, although the concentration is significantly different across different species. For instance, Citrus aurantium subsp. (C.) reticulata boasts an NG content of 3383.6 μg/mL, while C. bergamia, on the other hand, contains a significantly lower quantity at 22.3 μg/mL. Notably, in C. paradisi, NG significantly surpasses other common citrus flavonoids, making it the dominant compound [2]. Meanwhile, NG is mainly found in the waste of fruit and vegetable products such as citrus peel. Yu Matsuo et al. obtained NG from C. natsudaidai peel waste extract with a yield of 23.8–27.0 mg/g dried material, which had a better odor than commercial citrus-flavor drinks [3]. Research on the biological activities of NG and the improvement of bioavailability is conducive to the comprehensive utilization of product waste and increases the added value of related products.

2. Anti-Inflammatory

NG exhibits potent anti-inflammatory properties, efficaciously mitigating acute inflammation instigated by pro-inflammatory factors. Overproduction of inflammatory mediators such as free radicals, cytokines, and chemokines, along with an escalated infiltration of inflammatory and immune cells, disrupt cellular and tissue functions and are associated with several acute and chronic diseases [21][4]. Specifically in macrophages, NG has been found to significantly suppress the production of inflammatory factors such as nitric oxide (NO), nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), tumor necrosis factor-α (TNF-α), and interleukin 6 (IL-6). Moreover, NG also inhibits the activation of nuclear factor kappa-B (NF-κB) induced by lipopolysaccharide (LPS) in cells [22][5]. NF-κB serves as a pivotal mediator in cellular responses to external stimuli, often acting as an initial responder that potentially intensifies the expression of inflammatory factors [23][6]. In this context, NG’s role in inhibiting the activation of NF-κB has emerged as particularly significant, given its anti-inflammatory potential. Meanwhile, a study by Liu et al. demonstrated that NG alleviates the secretion of lung-tissue myeloperoxidase (MPO), iNOS activity, and TNF-α expression in a dose-dependent manner in LPS-induced inflammation mice. Concurrently, the degradation of the inhibitor of nuclear factor kappa-B-alpha (IĸB-α) and the translocation of protein NF-κB p65 are hindered, effectively inactivating NF-κB activation. These findings suggest that NG might exert substantial anti-inflammatory effects in lungs exposed to LPS, likely by inhibiting NF-κB activation [24][7]. Therefore, NG has been demonstrated to have significant potential as an effective anti-inflammatory agent.

3. Anti-Diabetes

Insulin resistance is a fundamental pathological feature of type 2 diabetes, often exacerbated by the impairment of insulin signaling. This impairment significantly aggravates diabetes symptoms by reducing insulin efficacy [25][8]. Research has demonstrated that NG ameliorates insulin resistance induced by a high-fat diet through the activation of the insulin pathway (phosphatidyl inositol 3 kinase (PI3K)/protein kinase B (PKB or AKT) and glucose transporters 4 (GLUT4) translocation. This activation induces GLUT4′s translocation to the plasma membrane), therefore facilitating a decrease in blood glucose levels [26][9]. In addition, NG enhances glucose uptake by promoting the translocation of GLUT2 in HepG2 cells under high glucose conditions. At the same time, it suppresses hepatic gluconeogenesis and promotes glycogen synthesis by activating the adenosine 5’-monophosphate (AMP)-activated protein kinase (AMPK) pathway. As a result, blood glucose is absorbed by the peripheral organs, effectively reducing blood glucose levels [27][10]. Therefore, NG could be used as a potential candidate for treating type 2 diabetes. Moreover, NG has demonstrated potential for ameliorating diabetic nephropathy (DN), a typical complication of type 1 and type 2 diabetes. Zhang et al. found that NG suppressed the expression of NADPH oxidase 4 (NOX4) at both mRNA and protein levels through in vivo and in vitro model experiments of DN. The down-regulation of NOX4 notably reduces the expression level of Cleaved caspase3 in podocytes, resulting in significant suppression of apoptosis and reactive oxygen species levels. Meanwhile, it curtails the excessive accumulation of extracellular matrix (ECM) in mesangial and renal tubular cells, alleviating streptozotocin-induced oxidative stress injury and mitigating apoptosis and highly reactive oxygen species levels triggered by high glucose levels [28][11]. Therefore, NG has been demonstrated to have a therapeutic effect on DN complications, primarily through the mitigation of histiocytic symptoms associated with DN.

4. Hepatoprotective Activity

NG has been identified as a potential therapeutic agent in ameliorating symptoms of hepatic disease. Research conducted by Rossana Bugianesi et al. illustrated that NG is predominantly metabolized in the liver, and after oral ingestion of tomato paste rich in NG glycosides, it circulated in the body as a conjugated form [29][12]. This implied that NG sourced from plant-based foods is effectively absorbed by the body, enhancing its bioavailability. As a result, it can significantly contribute to preventing and treating liver disease in humans. Research has shown that NG (25 mg/L) effectively reduces alcohol-induced lipid accumulation in the subcutaneous layers and liver of the zebrafish model. Meanwhile, hepatocyte steatosis was inhibited, and liver damage caused by fat deposition was improved [28][11]. In further research, fat deposition was improved by decreasing the formation and accumulation of reactive oxygen species (ROS) in the liver [30][13]. Meanwhile, NG has the potential to regulate oxidative pressure and inhibit hepatocyte injury. In the experiment, NG treatment at 5 mg/L for 48 h significantly reduced the alcohol-induced lipid droplet accumulation in the livers of exposed larvae with a dose-dependent tendency. More specifically, NG significantly reduced the oxidative stress gene expression of cyp2y3 and fabp10α, which was induced by alcohol. Both oxidative stress genes were involved in the regulation of fatty acid metabolism and lipid uptake and transport. Furthermore, in zebrafish, the closest cyp2e1 homolog was cyp2y3, which is 43% identical to the human protein. NG also reduced hepatocyte apoptosis of zebrafish larvae in experiments of terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling (TUNEL) staining, and played a positive role in anti-apoptosis. Moreover, NG exhibits the physiological activity of anti-apoptosis. Some related factors that cause lipid metabolism disorder, endoplasmic reticulum stress, and DNA damage were downgraded due to the intake of NG, and the phenomenon of apoptosis was reduced [31][14]. In addition, NG has been demonstrated to have significant efficacy in mitigating nonalcoholic fatty liver disease (NAFLD). First, NG reduced hepatic steatosis in rats subjected to a high-fat diet. This hepatoprotective activity appeared to be partially mediated by the activation of the AMPK pathway. Upon the activation of the AMPK pathway, there was a consequent re-establishment of reduced antioxidant enzyme activities, comprising superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx), and glutathione S-transferase (GST), as well as prevented inflammation [32][15]. The increase in antioxidant enzyme activities enhances liver detoxification and protects the liver from free-radical damage [33][16]. Meanwhile, NG has been shown to have significant potential in ameliorating the symptoms of cadmium-induced hepatotoxicity (at a concentration of 50 mg/kg NG) and nickel-induced hepatotoxicity (at 80 mg/kg NG) (Table 1). These were demonstrated by a notable decrease in lipid peroxidation and a substantial increase in the activity of antioxidant enzymes in rats [34][17]. Moreover, naringenin (50 mg/kg, an aglycone of NG) was shown to have a remarkably restorative effect on liver function abnormalities induced by dimethylnitrosamine (DMN) in mice [35][18]. In summary, the demonstrated hepatoprotective activities of NG substantiate its potential as a promising therapeutic candidate for liver diseases, highlighting its value for further clinical research.

5. Neuroprotective Activity

NG has been demonstrated to have tremendous potential for the prevention and therapeutic intervention of neurodegenerative diseases such as Parkinson’s disease, epilepsy, Huntington’s disease, and Alzheimer’s disease (AD) (Table 1). Investigations have revealed that NG has a protective effect on viable neurons affected by 3-nitropropionic (3-NP), a succinate dehydrogenase inhibitor known to induce neuronal injury and death in rats. This protective effect has been demonstrated by the reduction of radical species such as hydroxyl radical (29.36%), hydroperoxide radical (36.32%), and nitrite radical (45.62%) in 3-NP-treated rats. Moreover, NG ameliorated the tissue damage caused by 3-NP exposure by enhancing the GSH/GSSG ratio value by 74.17%. Additionally, NG significantly increased mRNA expressions of HO-1, NQO-1, GST-P1, and c-GCL by 60.78%, 72.5%, 64.71%, and 55.79%, respectively, in the treated rats compared with the 3-NP-induced group. Impressively, these expressions exceeded 75% compared to the control group of rats [36][19]. These increases were significant since HO-1, NQO-1, GST-P1, and c-GCL were induced by the nuclear erythroid 2-related factor 2 (Nrf2) [37,38][20][21]. Consequently, the pronounced neuroprotective effect of NG can be attributed to its potent antioxidant activity, mediated through the Nrf2 signaling cascade. NG has been seen to protect neurons by stimulating the production of neurotrophic factors and activating the Nrf2 signal transduction pathway [39][22]. In the case of AD patients, there is typically an overactivation of pro-inflammatory M1-type cells in the brain tissue, leading to excessive secretion of pro-inflammatory factors and cytotoxic substances [40][23]. NG has been shown to mitigate cognitive impairment in AD patients by regulating the balance of pro-inflammatory cells (M1 type) and anti-inflammatory cells (M2 type). Furthermore, NG improves abnormal behavioral features by enhancing the phagocytosis and clearance of Aβ-oligomer, therefore offsetting neurotoxicity and neuroinflammation [41][24]. This finding has established a theoretical framework for treating AD and presents a novel therapeutic approach. In short, NG offers promise as a prospective medication for treating and preventing neurodegenerative disorders.

6. The Drug Absorption Enhancer

NG and its derivatives play roles as solubilizers, boosting the absorption of other drugs, and elevating their bioavailability, as demonstrated in drugs such as paclitaxel, diltiazem, candesartan, and pranlukast. Paclitaxel, an anticancer drug, is characterized by poor solubility and challenging absorption into the body, predominantly due to the exocytosis of p-glycoprotein (p-gp) at the top of the intestinal epithelial cells [42][25]. Owing to these complexities, paclitaxel is mainly administered through intravenous injection, which, unfortunately, is prone to induce allergic reactions, therefore limiting its clinical application. However, studies have reported an elevated plasma concentration of paclitaxel when co-administered with NG’s prodrug 7-mPEG 5000-succinyloxymethyloxycarbonyl-paclitaxel, compared to when paclitaxel was administered alone [18][26]. This phenomenon suggests that NG effectively improves the bioavailability of paclitaxel, presenting a promising avenue for the development of oral paclitaxel medicines. Similarly, NG also enhances the bioavailability of diltiazem, a calcium-channel antagonist. It has been shown that metabolic enzymes and p-glycoprotein impede the absorption of diltiazem [43][27]. However, upon administration of NG (5 or 15 mg/kg), both the area under the plasma concentration–time curve (AUC) and the peak concentration (Cmax) have been observed to double, indicating significant changes in pharmacokinetics and a marked improvement in bioavailability. In addition, Surampalli et al. explored the effect of NG on the absorption of candesartan (an antihypertensive drug) within the intestinal tract of rats using a single-channel perfusion model (Table 1). Their results illustrated that the lyophilized solid dispersion of NG significantly increases the maximum concentration (Cmax) of candesartan and shortens the time (tmax) to reach Cmax compared to when the drug was administered alone. This outcome was attributed to low concentrations of NG substantially inhibiting the function of p-glycoprotein [44][28]. Moreover, α-glycosylated NG significantly increased the apparent solubility of pranlukast hemihydrate (PLH, a drug used to treat bronchial asthma) in distilled water at 37 °C, as per the dissolution test. The apparent solubility of PLH increased from 0.17 ± 0.01 μg/mL in the control group to 14.54 ± 1.32 μg/mL, and this increase was proportional to the concentration of α-glycosylated NG [20][29]. Concurrently, the AUC of the physical mixture of PLH with α-glycosylated NG was 2.2 times greater than that of the PLH treatment alone in a rat model, indicating that α-glycosylated NG improved the oral absorption of PLH [20][29]. In summary, NG has emerged as a potential active ingredient capable of improving the bioavailability of drugs with poor solubility, reinforcing its pivotal role in drug absorption enhancement. These characteristics of NG, which greatly limit its application in practical production, mainly include low solubility, low permeability, short half-life, high plasma concentration fluctuation, bitter taste, and toxicity at high concentrations (≥200 μg/mL) [11][30]. Therefore, the solubilization of NG and the improvement of its bioavailability have become research hotspots. The solubilization methods of NG are summarized in the following table, including structural modification, solid dispersion, liposomes, preparation of nanoparticles, and amphiphilic molecular encapsulation, to provide a reference for solving NG’s poor-solubility problem.
Table 1.
The physiological activities of naringin.

Physiological Activities



Animal Model

Potential Mechanisms




100 mg/kg

HFD-induced obesity mice

Decrease: Mac-2, MCP-1, JNK phosphorylation


36.8 mg/kg

CS-induced chronic bronchitis in guinea pigs

Increase: Activities of SOD and LXA4

Decrease: IL-8, LTB4, TNF-α, BALF, and myeloperoxidase activity


60 mg/kg

LPS-induced endotoxin shock in mice

Decrease: NO, TNF-α, IL-6, iNOS, COX-2 and transcriptional activity of NF-κB


3 mg

LPS/D-galactosamine-induced liver injury mice

Decrease: AST, ALT, CK, TNF-α




30 mg/kg

STZ-induced diabetic mice

Increase: Activity of hexokinase

Decrease: Activities of glucose-6-phosphatase and fructose-1,6-bisphosphatase in the liver and kidney


200 mg/kg

C57BL/KsJ-db/db mice (Diabetic mouse model)

Increase: Hepatic glucokinase activity and glycogen concentration

Decrease: Activity of hepatic G6-P and phosphoenolpyruvate carboxykinase



50 mg/kg

STZ-nicotinamide–induced diabetes mice

Increase: Serum insulin concentrations

Decrease: Activities of ALT, AST, ALP, and LDH in serum, Concentrations of fasting blood glucose, Glycosylated hemoglobin



50 mg/kg

HFD/STZ-nicotinamide–induced diabetes mice

Increase: G6Pase, Glycogen phosphorylase, FBPase, Insulin release

Decrease: MDA, NO, TNF-α, IL-2


Hepatoprotective activity


80 mg/kg (Nickel) and 50 mg/kg (Cadmium)

Nickel and Cadmium-induced hepatotoxicity in mice

Increase: SOD, CAT, GPx, GST, GST, GSH, vitamin C, and vitamin E

Decrease: AST, ALT, ALP, LDH, GGT, TB, The liver nickel concentration, Lipid peroxidation indices, and protein carbonyl contents



50 mg/kg

DMN-induced liver injury mice

Increase: Body weight, Serum albumin, and total protein levels

Decrease: ALT, AST, ALP, and bilirubin levels, MDA, Hepatic stellate cell activation



20 mg/kg

APAP induced in male Wistar mice

Increase: Albumin, IL-4, GSH, SOD, GST, GPx, Bcl-2

Decrease: AST, ALT, ALP, LDH, GGT bilirubin, lipid, TNF-α,

lipid peroxidation p53, Bax, CASP-3



25 mg/L

2% ethanol-induced larvae of zebrafish

Increase: Cyp2y3 and Fabp10α, Histological injury severity, Apoptotic cell death, and SOD radical levels



100 mg/kg

5-fluorouracil induced liver and kidney toxicity in mice

Increase: GSH, SOD

Decrease: ALT, AST, ALP, MDA, IL-1α, TNF-α, IL-6


Neuroprotective Activity


80 mg/kg

3-NP-induced neurodegenerative disease in mice

Increase: Nuclear translocation of Nrf2, Induce phase II genes such as HO-1, NQO-1, GST-P1 and γ-GCL expression

Decrease: TNF-α, COX-2, and iNOS mRNA expression


80 mg/kg

KA-induced neurodegenerative disease in mice

Increase: Protected hippocampal CA1 neurons, the expression of LC3

Decrease: TNF-α, Occurrence of SRS


100 mg/kg

Aβ-induced AD mice

Increase: CaMKII activity, Phosphorylation of AMPA, Improved long-term learning and memory ability

Decrease: GSK-3β activity


200 mg/kg

ICV-STZ-induced AD mice

Increase: CAT, SOD, GSH, Mitochondrial complex (I, II, and IV)

Decrease: Cholinesterase activity, MDA, nitrate level, TNF-α, IL-1β


The drug Absorption Enhancer


PLH 40 mg/kg/NG 80 mg/kg

Male Sprague–Dawley mice

Increase: PLH solubility and absorption



15 mg/kg

in-situ rat models

Increase: Candesartan absorption, AUC value, and Cmaxvalue

Decrease: tmaxvalue, the release of protein and ALP


Preparation of GGTN composite with NG

10 mg/mL

Rabbit skull defect model

Increase: Bone regeneration, bone conduction activity, new bone growth, wound healing


Abbreviations: HFD, High-fat diet; MCP-1, monocyte chemoattractant protein-1; JNK, C-Jun N-terminal kinases; CS, Chronic cigarette smoke; SOD, superoxide dismutase; LXA4, the content of lipoxin A4; IL-8, Interleukin-8; LTB4, leukotriene B4; TNF-α, Tumor necrosis factor α; BALF, bronchoalveolar lavage fluid; MPO, myeloperoxidase activity; LPS, lipopolysaccharide; NO, Nitric oxide;IL-6,Interleukin-6; iNOS, inducible nitric oxide synthase; COX-2,cyclooxygenase; NF-kB, kappa-light-chain-enhancer of activated B cells; ALT, alanine transaminase; AST, aspertate transaminase; CK, creatine kinase; STZ, streptozotocin; G6-P, glucose 6-phosphate; G6Pase, Glucose-6-phosphatase; FBPase, fructose-1, 6 bisphosphatase; MDA, malondialdehyde; PLH, pranlukast hemihydrate; IL-2,Interleukin-2; LDH, lactate dehydrogenase; GGT, γ-glutamyl transferase; TB, serum total bilirubin; CAT, catalase; GPx, glutathione peroxidase; GST, glutathione S-transferase; GSH, glutathione; ALP, alkaline phosphatase; DMN, dimethylnitrosamine; APAP, N-Acetyl-p-aminophenol; IL-4, Interleukin-4; Bcl-2, lymphoma 2; Bax, Bcl-2 associated X; CASP-3, cysteine aspartate-specific protease-3; cyp2y3, cytochrome P450 family 2 subfamily Y polypeptide 3; Fabps, Fatty acid-binding proteins; IL-1α, interleukin-1α; 3-NP, 3-nitropropionic acid; Nrf2, Nuclear factor-erythroid 2-related factor-2; HO-1,heme oxygenase-1; NAD(P)H, quinone oxidoreductase-1; NQO-1, NAD(P)H: quinone oxidoreductase-1; GST-P1,glutathione S-transferase P1; γGCl, γ-glutamylcysteine ligase; KA, Kainic acid; LC3, microtubule-associated protein light chain 3; SRS, spontaneous recurrent seizures; Aβ, Amyloid-β; AD, Alzheimer’s disease; CaMKII, calcium/calmodulin-dependent protein kinase II; AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic; GSK-3β, Glycogen synthase kinase-3β; PLH, pranlukast hemihydrate.


  1. Ghanbari-Movahed, M.; Jackson, G.; Farzaei, M.H.; Bishayee, A. A systematic review of the preventive and therapeutic effects of naringin against human malignancies. Front. Pharmacol. 2021, 12, 639840.
  2. Bilbao, M.d.L.M.; Andrés-Lacueva, C.; Jáuregui, O.; Lamuela-Raventos, R.M. Determination of flavonoids in a Citrus fruit extract by LC–DAD and LC–MS. Food Chem. 2007, 101, 1742–1747.
  3. Matsuo, Y.; Akita, K.; Taguchi, H.; Fujii, S.; Yoshie-Stark, Y.; Araki, T. Utilization and evaluation of Citrus natsudaidai peel waste as a source of natural food additives. Food Chem. 2022, 373, 131464.
  4. Lai, C.-S.; Wu, J.-C.; Ho, C.-T.; Pan, M.-H. Disease chemopreventive effects and molecular mechanisms of hydroxylated polymethoxyflavones. BioFactors 2015, 41, 301–313.
  5. Bharti, S.; Rani, N.; Krishnamurthy, B.; Arya, D.S. Preclinical evidence for the pharmacological actions of naringin: A review. Planta Med. 2014, 80, 437–451.
  6. Lepetsos, P.; Papavassiliou, K.A.; Papavassiliou, A.G. Redox and NF-κB signaling in osteoarthritis. Free Radic. Biol. Med. 2019, 132, 90–100.
  7. Liu, Y.; Wu, H.; Nie, Y.-C.; Chen, J.-L.; Su, W.-W.; Li, P.-B. Naringin attenuates acute lung injury in LPS-treated mice by inhibiting NF-κB pathway. Int. Immunopharmacol. 2011, 11, 1606–1612.
  8. Martín, M.Á.; Ramos, S. Dietary Flavonoids and Insulin Signaling in Diabetes and Obesity. Cells 2021, 10, 1474.
  9. Sandeep, M.S.; Nandini, C.D. Influence of quercetin, naringenin and berberine on glucose transporters and insulin signalling molecules in brain of streptozotocin-induced diabetic rats. Biomed. Pharmacother. 2017, 94, 605–611.
  10. Dayarathne, L.A.; Ranaweera, S.S.; Natraj, P.; Rajan, P.; Lee, Y.J.; Han, C.-H. The effects of naringenin and naringin on the glucose uptake and AMPK phosphorylation in high glucose treated HepG2 cells. J. Vet. Sci. 2021, 22, e92.
  11. Zhang, J.; Yang, S.; Li, H.; Chen, F.; Shi, J. Naringin ameliorates diabetic nephropathy by inhibiting NADPH oxidase 4. Eur. J. Pharm. 2017, 804, 1–6.
  12. Bugianesi, R.; Catasta, G.; Spigno, P.; D’Uva, A.; Maiani, G. Naringenin from cooked tomato paste is bioavailable in men. J. Nutr. 2002, 132, 3349–3352.
  13. Huang, B.B.; Liu, D.X.; Liu, D.K.; Wu, G. Application of solid dispersion technique to improve solubility and sustain release of emamectin benzoate. Molecules 2019, 24, 4315.
  14. Lin, H.; Zhou, Z.; Zhong, W.; Huang, P.; Ma, N.; Zhang, Y.; Zhou, C.; Lai, Y.; Huang, S.; An, H.; et al. Naringenin inhibits alcoholic injury by improving lipid metabolism and reducing apoptosis in zebrafish larvae. Oncol. Rep. 2017, 38, 2877–2884.
  15. Shirani, K.; Yousefsani, B.S.; Shirani, M.; Karimi, G. Protective effects of naringin against drugs and chemical toxins induced hepatotoxicity: A review. Phytother. Res. 2020, 34, 1734–1744.
  16. Adwas, A.A.; Elsayed, A.; Azab, A.; Quwaydir, F. Oxidative stress and antioxidant mechanisms in human body. J. Appl. Biotechnol. Bioeng. 2019, 6, 43–47.
  17. Pari, L.; Amudha, K. Hepatoprotective role of naringin on nickel-induced toxicity in male Wistar rats. Eur. J. Pharmacol. 2011, 650, 364–370.
  18. Lee, M.-H.; Yoon, S.; Moon, J.-O. The flavonoid naringenin inhibits dimethylnitrosamine-induced liver damage in rats. Biol. Pharm. Bull. 2004, 27, 72–76.
  19. Gopinath, K.; Sudhandiran, G. Naringin modulates oxidative stress and inflammation in 3-nitropropionic acid-induced neurodegeneration through the activation of nuclear factor-erythroid 2-related factor-2 signalling pathway. Neuroscience 2012, 227, 134–143.
  20. Mani, V.M.; Sadiq, A.M.M. Flavonoid naringin inhibits microglial activation and exerts neuroprotection against deltamethrin induced neurotoxicity through Nrf2/ARE signaling in the cortex and hippocampus of rats. World J. Pharm. Sci. 2015, 3, 2292–2514.
  21. Ramful-Baboolall, D.; Neergheen-Bhujun, V.; Bahorun, T. Prophylactic propensity of citrus phytochemicals: Action and mechanisms. Mol. Phylogeny Antioxid. Prop. Med. Uses 2014, 95, 95–98.
  22. Budel, R.G.; da Silva, D.A.; Moreira, M.P.; Dalcin, A.J.F.; da Silva, A.F.; Nazario, L.R.; Majolo, J.H.; Lopes, L.Q.S.; Santos, R.C.V.; Soares, F.A.A. Toxicological evaluation of naringin-loaded nanocapsules in vitro and in vivo. Colloids Surf. B Biointerfaces 2020, 188, 110754.
  23. Li, Q.; Wu, Y.; Chen, J.; Xuan, A.; Wang, X. Microglia and immunotherapy in Alzheimer’s disease. Acta Neurol. Scand. 2022, 145, 273–278.
  24. Ruan, Q.; Ruan, J.; Zhang, W.; Qian, F.; Yu, Z. Targeting NAD+ degradation: The therapeutic potential of flavonoids for Alzheimer’s disease and cognitive frailty. Pharmacol. Res. 2018, 128, 345–358.
  25. Sparreboom, A.; Van Asperen, J.; Mayer, U.; Schinkel, A.H.; Smit, J.W.; Meijer, D.K.; Borst, P.; Nooijen, W.J.; Beijnen, J.H.; Van Tellingen, O. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc. Natl. Acad. Sci. USA 1997, 94, 2031–2035.
  26. Choi, J.-S.; Shin, S.-C. Enhanced paclitaxel bioavailability after oral coadministration of paclitaxel prodrug with naringin to rats. Int. J. Pharm. 2005, 292, 149–156.
  27. Yeung, P.; Mosher, S.J.; Quilliam, M.A.; Montague, T.J. Species comparison of pharmacokinetics and metabolism of diltiazem in humans, dogs, rabbits, and rats. Drug Metab. Dispos. 1990, 18, 1055–1059.
  28. Surampalli, G.; Nanjwade, B.K.; Patil, P. Corroboration of naringin effects on the intestinal absorption and pharmacokinetic behavior of candesartan cilexetil solid dispersions using in-situ rat models. Drug Dev. Ind. Pharm. 2015, 41, 1057–1065.
  29. Uchiyama, H.; Kadota, K.; Nakanishi, A.; Tandia, M.; Tozuka, Y. A simple blending with α-glycosylated naringin produces enhanced solubility and absorption of pranlukast hemihydrate. Int. J. Pharm. 2019, 567, 118490.
  30. Dai, K.-R.; Yan, S.-G.; Yan, W.-Q.; Chen, D.-Q.; Xu, Z.-W. Effects of naringin on the proliferation and osteogenic differentiation of human bone mesenchymal stem cell. Eur. J. Pharmacol. 2009, 607, 1–5.
  31. Yoshida, H.; Watanabe, H.; Ishida, A.; Watanabe, W.; Narumi, K.; Atsumi, T.; Sugita, C.; Kurokawa, M. Naringenin suppresses macrophage infiltration into adipose tissue in an early phase of high-fat diet-induced obesity. Biochem. Biophys. Res. Commun. 2014, 454, 95–101.
  32. Luo, Y.-L.; Zhang, C.-C.; Li, P.-B.; Nie, Y.-C.; Wu, H.; Shen, J.-G.; Su, W.-W. Naringin attenuates enhanced cough, airway hyperresponsiveness and airway inflammation in a guinea pig model of chronic bronchitis induced by cigarette smoke. Int. Immunopharmacol. 2012, 13, 301–307.
  33. Kanno, S.-i.; Shouji, A.; Tomizawa, A.; Hiura, T.; Osanai, Y.; Ujibe, M.; Obara, Y.; Nakahata, N.; Ishikawa, M. Inhibitory effect of naringin on lipopolysaccharide (LPS)-induced endotoxin shock in mice and nitric oxide production in RAW 264.7 macrophages. Life Sci. 2006, 78, 673–681.
  34. Kawaguchi, K.; Kikuchi, S.; Hasegawa, H.; Maruyama, H.; Morita, H.; Kumazawa, Y. Suppression of lipopolysaccharide-induced tumor necrosis factor-release and liver injury in mice by naringin. Eur. J. Pharmacol. 1999, 368, 245–250.
  35. Alam, M.A.; Subhan, N.; Rahman, M.M.; Uddin, S.J.; Reza, H.M.; Sarker, S.D. Effect of citrus flavonoids, naringin and naringenin, on metabolic syndrome and their mechanisms of action. Adv. Nutr. 2014, 5, 404–417.
  36. Jung, U.J.; Lee, M.-K.; Jeong, K.-S.; Choi, M.-S. The hypoglycemic effects of hesperidin and naringin are partly mediated by hepatic glucose-regulating enzymes in C57BL/KsJ-db/db mice. J. Nutr. 2004, 134, 2499–2503.
  37. Annadurai, T.; Muralidharan, A.R.; Joseph, T.; Hsu, M.; Thomas, P.; Geraldine, P. Antihyperglycemic and antioxidant effects of a flavanone, naringenin, in streptozotocin–nicotinamide-induced experimental diabetic rats. J. Physiol. Biochem. 2012, 68, 307–318.
  38. Mahmoud, A.M.; Ashour, M.B.; Abdel-Moneim, A.; Ahmed, O.M. Hesperidin and naringin attenuate hyperglycemia-mediated oxidative stress and proinflammatory cytokine production in high fat fed/streptozotocin-induced type 2 diabetic rats. J. Diabetes Its Complicat. 2012, 26, 483–490.
  39. Renugadevi, J.; Prabu, S.M. Cadmium-induced hepatotoxicity in rats and the protective effect of naringenin. Exp. Toxicol. Pathol. 2010, 62, 171–181.
  40. Ahmed, O.M.; Fahim, H.I.; Ahmed, H.Y.; Al-Muzafar, H.M.; Ahmed, R.R.; Amin, K.A.; El-Nahass, E.S.; Abdelazeem, W.H. The Preventive Effects and the Mechanisms of Action of Navel Orange Peel Hydroethanolic Extract, Naringin, and Naringenin in N-Acetyl-p-aminophenol-Induced Liver Injury in Wistar Rats. Oxid. Med. Cell. Longev. 2019, 2019, 2745352.
  41. Zhou, C.; Lai, Y.; Huang, P.; Xie, L.; Lin, H.; Zhou, Z.; Mo, C.; Deng, G.; Yan, W.; Gao, Z.; et al. Naringin attenuates alcoholic liver injury by reducing lipid accumulation and oxidative stress. Life Sci. 2019, 216, 305–312.
  42. Gelen, V.; Şengül, E.; Yıldırım, S.; Atila, G. The protective effects of naringin against 5-fluorouracil-induced hepatotoxicity and nephrotoxicity in rats. Iran. J. Basic Med. Sci. 2018, 21, 404–410.
  43. Jeong, K.H.; Jung, U.J.; Kim, S.R. Naringin Attenuates Autophagic Stress and Neuroinflammation in Kainic Acid-Treated Hippocampus In Vivo. Evid. Based Complement. Altern. Med. 2015, 2015, 354326.
  44. Wang, D.M.; Yang, Y.J.; Zhang, L.; Zhang, X.; Guan, F.F.; Zhang, L.F. Naringin Enhances CaMKII Activity and Improves Long-Term Memory in a Mouse Model of Alzheimer’s Disease. Int. J. Mol. Sci. 2013, 14, 5576–5586.
  45. Sachdeva, A.K.; Kuhad, A.; Chopra, K. Naringin ameliorates memory deficits in experimental paradigm of Alzheimer’s disease by attenuating mitochondrial dysfunction. Pharm. Biochem. Behav. 2014, 127, 101–110.
  46. Chen, K.Y.; Lin, K.C.; Chen, Y.S.; Yao, C.H. A novel porous gelatin composite containing naringin for bone repair. Evid. Based Complement. Altern. Med. 2013, 2013, 283941.
Video Production Service